HLA-B*5701 screening for hypersensitivity to abacavir¶
Mallal, S., Phillips, E., & Carosi, G. (2008). HLA-B*5701 screening for hypersensitivity to abacavir. The New England Journal of Medicine.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Domain-specific¶
- Adverse Drug Reaction
- The PREDICT-1 randomized study (Mallal and colleagues, New England Journal of Medicine, 2008) then showed that screening patients for HLA-B*5701 before prescribing, and withholding abacavir from carriers, abolished immunologically confirmed hypersensitivity
This sourcePREDICT-1, the double-blind randomised study of prospective HLA-B*5701 screening with exclusion of carriers to prevent abacavir hypersensitivity.
Supported in partVerified against the publisher's abstract
“This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir.”
- The PREDICT-1 randomized study (Mallal and colleagues, New England Journal of Medicine, 2008) then showed that screening patients for HLA-B*5701 before prescribing, and withholding abacavir from carriers, abolished immunologically confirmed hypersensitivity
Verification¶
Does it exist? Not checked yet. This work's DOI is recorded above but has not been resolved against an external catalogue, so nothing here confirms the work exists.
Does it back the claim? Read against the text for 1 of 1 citation: 1 supported in part. Each verdict is shown under its citation below, with what in the work backs the sentence.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:28e8b68503b9 · see in the full table